METTL1 and neoplasm: Importantly, overexpression of METTL1 or BRCA1 counteracted the anti-tumor effects of 5-formamidoimidazole-4-carboxamide ribotide (Fig. 6K (28 d, all p < 0.0001) and Fig. 6L (Control vs. FAICAR + oe-NC, p < 0.0001.